PTGX
Protagonist Therapeutics Inc

3,356
Mkt Cap
$5.29B
Volume
755,426.00
52W High
$93.25
52W Low
$33.31
PE Ratio
133.58
PTGX Fundamentals
Price
$84.61
Prev Close
$83.24
Open
$82.18
50D MA
$71.05
Beta
0.52
Avg. Volume
1.46M
EPS (Annual)
$4.23
P/B
8.19
Rev/Employee
$3.45M
Loading...
Loading...
News
all
press releases
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC
Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.5% during the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
135,050 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nan Fung Trinity HK Ltd.
Nan Fung Trinity HK Ltd. purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·3d ago
News Placeholder
Profund Advisors LLC Has $1.05 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
Profund Advisors LLC boosted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 65.0% in the second quarter, according to its most recent filing with the...
MarketBeat·3d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $98.00 at Citigroup
Citigroup lifted their price target on shares of Protagonist Therapeutics from $96.00 to $98.00 and gave the stock a "buy" rating in a research note on Monday...
MarketBeat·5d ago
News Placeholder
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the company...
MarketBeat·5d ago
News Placeholder
What is Wedbush's Forecast for PTGX FY2029 Earnings?
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities research analysts at Wedbush decreased their FY2029 earnings per share estimates for shares of Protagonist Therapeutics in a...
MarketBeat·6d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate...
MarketBeat·7d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $81.00
JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an "overweight" rating in a research note on Friday...
MarketBeat·8d ago
News Placeholder
Barclays Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $88.00
Barclays upped their price objective on Protagonist Therapeutics from $72.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday...
MarketBeat·8d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Citizens Jmp Analyst Says
Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a "market outperform" rating in a research note on Friday...
MarketBeat·8d ago

Latest PTGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.